<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8"/>
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
  <meta name="title" content="Novartis presents latest Phase III Fabhalta® ( iptacopan ) data in C3 glomerulopathy ( C3G ) showing …"/>
  <meta name="description" content="One of the world s most successful drugs, Novartis, has revealed a significant reduction in proteinuria in patients treated with C3G glomerulopathies (C3) within 10 years, according to preliminary results from the latest clinical trials. These are the key takeaways from this study. A summary of …"/><meta name="robots" content="index,follow"/><link rel="canonical" href="https://datosabiertos.com/open_data/2024-05-25/novartis-presents-latest-phase-iii-fabhalta-r-iptacopan-data-in-c3-glomerulopathy-c3g-showing-clinically-meaningful-and-statistically-significant-35-1/">
  <link rel="icon" href="/img/favicon.ico"/>

  <title>Novartis presents latest Phase III Fabhalta® ( iptacopan ) data in C3 glomerulopathy ( C3G ) showing clinically meaningful and statistically significant 35 . 1 % proteinuria reduction vs . placebo - Open Data</title>

  <link rel="preload" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
  <noscript><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css" integrity="sha384-xOolHFLEh07PJGoPkLv1IbcEPTNtaed2xpHsD9ESMhqIYd0nLMwNLD69Npy4HI+N" crossorigin="anonymous"></noscript>

  
  <link rel="stylesheet" href="/css/custom.css">
</head>

<body>
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MXMNS5J"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
  <main role="main" class="container">
    
    <header class="site-header py-3">
      <div class="row flex-nowrap justify-content-between align-items-center">
        <div class="col pt-1">
          <a class="site-header-name" href="/">
            <h1 class="site-header-name">Open Data</h1>
          </a>
        </div>
      </div>
    </header>
    

    
    <div class="container nav-bar">
      <div class="row nav">
        <a class="col-md-auto p-2" href="/es/">ES</a>
        <a class="col-md-auto p-2" href="/">EN</a>
      </div>
    </div>
    

    <div class="row">

      
      <div class="col">
        
<div class="content is-medium">
  <p class="article_item">
    <a href="https://www.prnewswire.com/news-releases/novartis-presents-latest-phase-iii-fabhalta-iptacopan-data-in-c3-glomerulopathy-c3g-showing-clinically-meaningful-and-statistically-significant-35-1-proteinuria-reduction-vs-placebo-302155372.html" target="_new">Novartis presents latest Phase III Fabhalta® ( iptacopan ) data in C3 glomerulopathy ( C3G ) showing clinically meaningful and statistically significant 35 . 1 % proteinuria reduction vs . placebo</a>
    <p>One of the world s most successful drugs, Novartis, has revealed a significant reduction in proteinuria in patients treated with C3G glomerulopathies (C3) within 10 years, according to preliminary results from the latest clinical trials. These are the key takeaways from this study. A summary of those reports. (). 1) The scientists have been told they are looking at the results of an investigation into the risks of kidney failure, and their safety assessments could be reviewed by the US regulators for the first time, but experts say the trial of its experimental drug, Fabholta, suggests it appears to have lowered proteinuri in urine protein and protein levels in some patients with severe inflammatory diseases which cause serious damage to the brain, as well as warnings that it is not being approved for emergency treatments in the UK, the BBC has learned about the impact of this illness - and it has been found to be inadequate evidence for its success. The first signs of success have emerged from early testing results published on the NHS, saying it was  significantly improved  during the Covid-19 pandemic, in what is expected to happen in England and Wales following the release of new data on human blood and blood vessels and the way it treats the disease while taking steps towards developing the treatment of C2G, writes BBC News Denmark.</p>
    <b style="font-weight: bold;">Source: <i>prnewswire.com</i></b>
    <br/>Published on <a href="/open_data/2024-05-25/">2024-05-25</a>
  </p>
</div>

    <div class="content is-medium">
        <h3>Related news</h3>
        <ul>
        
            <li><a href="/open_data/2023-07-17/uk-sees-surge-in-adhd-diagnoses/">UK Sees Surge in ADHD Diagnoses</a></li>
        
            <li><a href="/open_data/2023-01-19/mp-calls-for-end-to-river-sewage-discharges/">MP calls for end to river sewage discharges</a></li>
        
            <li><a href="/open_data/2022-12-01/seagate-technology-joins-the-active-archive-alliance/">Seagate Technology Joins the Active Archive Alliance</a></li>
        
            <li><a href="/open_data/2022-03-30/odi-sets-up-institute-to-promote-public-data-sharing/">ODI sets up institute to promote public data sharing</a></li>
        
            <li><a href="/open_data/2021-01-30/exclusive-interview-konsentu-backstory-and-the-acquisition-of-obe-from-preta/">Exclusive interview : Konsentu backstory and the acquisition of OBE from PRETA</a></li>
        
            <li><a href="/open_data/2021-12-16/new-model-improves-accuracy-of-machine-learning-in-covid-19-diagnosis-while-preserving-privacy/">New model improves accuracy of machine learning in COVID - 19 diagnosis while preserving privacy</a></li>
        
            <li><a href="/open_data/2024-05-25/novartis-presents-latest-phase-iii-fabhalta-r-iptacopan-data-in-c3-glomerulopathy-c3g-showing-clinically-meaningful-and-statistically-significant-35-1/">Novartis presents latest Phase III Fabhalta® ( iptacopan ) data in C3 glomerulopathy  ( C3G )  showing clinically meaningful and statistically significant 35 . 1 % proteinuria reduction vs . placebo</a></li>
        
            <li><a href="/open_data/2023-07-17/significant-rise-in-adhd-diagnoses-in-the-united-kingdom/">Significant rise in ADHD diagnoses in the united kingdom </a></li>
        
            <li><a href="/open_data/2021-11-18/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention/">New Analyses of Two AZD7442 COVID - 19 Phase III Trials in High - Risk Populations Confirm Robust Efficacy and Long - Term Prevention</a></li>
        
            <li><a href="/open_data/2022-09-20/prevalence-and-classification-of-misdiagnosis-among-hospitalised-patie/">Prevalence and Classification of Misdiagnosis Among Hospitalised Patie</a></li>
        
            <li><a href="/open_data/2021-12-02/collaboration-equals-innovation-how-can-the-eu-get-the-european-health-data-space-right/">Collaboration equals innovation : how can the EU get the European Health Data Space right ? </a></li>
        
            <li><a href="/open_data/2021-12-17/new-model-improves-accuracy-of-machine-learning-in-covid-diagnosis-while-preserving-privacy/">New model improves accuracy of machine learning in Covid diagnosis while preserving privacy</a></li>
        
            <li><a href="/open_data/2021-01-29/exclusive-interview-konsentu-backstory-and-the-acquisition-of-obe-from-preta/">Exclusive interview : Konsentu backstory and the acquisition of OBE from PRETA</a></li>
        
            <li><a href="/open_data/2023-02-07/global-genes-announces-completion-of-rare-x-merger-and-strategic-direction-for-combined-organization/">Global Genes Announces Completion of RARE - X Merger and Strategic Direction for Combined Organization</a></li>
        
        </ul>
    </div>
<div class="row">
  <div class="col-md-6">
    
      <a href="/open_data/2024-05-25/upward-social-mobility-linked-to-reduced-dementia-risk/">&laquo;&nbsp;Upward Social Mobility Linked to Reduced Dementia Risk</a>
    
  </div>
  <div class="col-md-6 text-right">
    
      <a href="/open_data/2024-05-25/">&#34;Novartis&#39; Fabhalta® Shows Promise in Treating Rare Kidney Disease: Positive Phase III Results Announced&#34; &nbsp;&raquo;</a>
    
  </div>
</div>

    </div>
  </main>

  <footer class="site-footer">

    <div class="row">
      <div class="col-md-3"></div>
      <div class="col-md-3 col-md-center">

      </div>
      <div class="col-md-3 col-md-center">

      </div>
    </div>
  </div>
  </footer>

  
  

  
  

<link href='https://www.googletagmanager.com' rel="preconnect" crossorigin>
  <link rel="dns-prefetch" href='https://www.googletagmanager.com'>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
    })(window,document,'script','dataLayer','GTM-MXMNS5J');</script>
  
  <script src="https://cdn.jsdelivr.net/npm/jquery@3.5.1/dist/jquery.slim.min.js" integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js" integrity="sha384-Fy6S3B9q64WdZWQUiU+q4/2Lc9npb8tCaSX9FK7E8HnRr0Jz8D6OP9dO5Vg3Q9ct" crossorigin="anonymous"></script>

</body>

</html>
